The paper by Joukamaa et al (2006, this issue) would have
interested Heinz Lehmann, a German émigré psychiatrist working at Verdun
hospital in Montreal, who was one of the first clinicians to investigate the
effects of chlorpromazine in North America and was the first to publish an
article outlining its clinical impact (Lehmann & Hanrahan, 1954).
Lehmann was no simple enthusiast for physical treatments, having
demonstrated that mute and deteriorated people with schizophrenia in
Verdun's back wards responded to placebo injections of ‘new experimental
hormones' when the injection site was painted with a disinfectant that left
a prominent red stain (Lehmann, 1993). However, chlorpromazine was
different. Although previous treatments had provided some benefits, nothing
produced quite such dramatic effects in the experience of senior researchers
such as Lehmann. Chlorpromazine ignited a wave of enthusiasm in psychiatry
sufficient to sweep aside post-War differences between the Germans and the
French, for instance, so that they and others convened to share their
experiences on the benefits of the new drugs at international meetings
rapidly organised by university departments rather than pharmaceutical
companies.